联合王国可能提高国民保健制度的药物阈值,以避免美国关税,使其定价与美国的水平一致。 UK may raise NHS drug threshold to avoid U.S. tariffs, align pricing with U.S. levels.

据报告,在前总统唐纳德·特朗普(Donald Trump)的威胁下,英国正在考虑将国民医疗系统的药物成本效益阈值提高25%,以避免美国对药品进口征收高达100%的潜在关税。 The UK is reportedly considering raising the NHS’s drug cost-effectiveness threshold by 25% to avoid potential U.S. tariffs of up to 100% on pharmaceutical imports, following threats from former President Donald Trump. 这一行动旨在使联合王国的药品定价与美国的水平更加接近,将允许核准更昂贵的药品供国民保健制度使用,从而增加总开支。 The move, aimed at aligning UK drug pricing more closely with U.S. levels, would allow more expensive medicines to be approved for NHS use, increasing overall spending. 这一变化是在担心当前价格压力导致主要制药公司暂停或取消英国投资的情况下发生的。 The change comes amid concerns that current pricing pressures have led major drug companies to pause or cancel UK investments. 政府表示正在与美国进行高级会谈, 以确保取得有利的结果, 强调制药部门对国民保健体系和经济的重要性, 并强调英国和美国的新生命科学伙伴关系。 The government says it is in advanced talks with the U.S. to secure a favorable outcome, emphasizing the importance of the pharmaceutical sector to the NHS and economy, and highlighting a new UK-US life sciences partnership.